CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,625,177 | +78.0% | 64,580 | +186.2% | 0.01% | +40.0% |
| Q3 2022 | $1,475,000 | +235.2% | 22,562 | +221.6% | 0.01% | +400.0% |
| Q1 2022 | $440,000 | -0.7% | 7,016 | +20.0% | 0.00% | -50.0% |
| Q4 2021 | $443,000 | -63.0% | 5,847 | -45.3% | 0.00% | -60.0% |
| Q3 2021 | $1,196,000 | +128.7% | 10,688 | +212.7% | 0.01% | +66.7% |
| Q4 2020 | $523,000 | -93.7% | 3,418 | -96.6% | 0.00% | -95.1% |
| Q3 2020 | $8,347,000 | +1805.7% | 99,802 | +1573.7% | 0.06% | +1425.0% |
| Q2 2020 | $438,000 | -91.5% | 5,963 | -94.6% | 0.00% | -87.9% |
| Q2 2019 | $5,165,000 | -44.7% | 109,657 | -39.1% | 0.03% | -21.4% |
| Q3 2018 | $9,340,000 | -61.7% | 180,000 | -56.7% | 0.04% | -62.2% |
| Q2 2018 | $24,415,000 | – | 415,500 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |